<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5264">
  <stage>Registered</stage>
  <submitdate>2/12/2015</submitdate>
  <approvaldate>2/12/2015</approvaldate>
  <nctid>NCT02621905</nctid>
  <trial_identification>
    <studytitle>Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc速 50 mg With Sporanox速 100 mg</studytitle>
    <scientifictitle>Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc速 (Mayne) Regardless of Food With Sporanox速 (Janssen) Under Fed Conditions</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MPG010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neutropenia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sporanox
Treatment: drugs - Lozanoc

Active Comparator: Sporanox - 100 mg

Experimental: Lozanoc - 50 mg


Treatment: drugs: Sporanox
At least 2 capsules twice a day for 3 weeks

Treatment: drugs: Lozanoc
At least 2 capsules twice a day for 3 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relative steady-state bioavailability</outcome>
      <timepoint>3 weeks</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of written, informed consent

          -  Age of at least 18 years

          -  No clinical evidence of active systemic fungal infection

          -  Physician-recommended primary prophylaxis against systemic fungal infections with
             itraconazole in patients who have had or about to have: a heart, lung or bone marrow
             transplant, combination chemotherapy for cancer; aspergilloma, chronic pulmonary
             aspergillus bronchitis, or allergic bronchopulmonary aspergillosis

          -  Patients may be receiving itraconazole prophylaxis prior to entry into the study

          -  Body mass index between 15.0 and 35.0 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant, planning pregnancy or breastfeeding

          -  Congestive cardiac failure or other causes of ventricular dysfunction that may
             outweigh the benefit of itraconazole

          -  Hypersensitivity to either study drug or to any of their excipients

          -  Coadministration of the following drugs:

               -  CYP3A4 metabolised substrates that can prolong the QT-interval e.g., sertindole,
                  terfenadine

               -  CYP3A4 metabolised HMG-CoA reductase inhibitors e.g. simvastatin, lovastatin

               -  Potent CYP3A4 inhibitors e.g. dronedarone

               -  Triazolam, alprazolam and oral midazolam

               -  Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and
                  ergotamine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mayne Pharma International Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The pharmacokinetics of Sporanox and Lozanoc has not been compared in patients requiring
      anti-fungal prophylaxis or therapy. The present study is designed to compare the
      pharmacokinetics of Sporanox and Lozanoc in patients requiring primary prophylaxis. The
      3-week exposure to each formulation is designed to allow for all participants to reach
      steady-state for each drug, as the time to steady-state can vary.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02621905</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Deborah Marriott</name>
      <address>St Vincent's Hospital, Sydney</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Deborah Marriott</name>
      <address />
      <phone>+612 8382 9196</phone>
      <fax />
      <email>dmarriott@stvincents.com.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>